Related Experiment Video
Updated: Jun 28, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Kidney injury, dialysis, and mortality with vancomycin plus piperacillin-tazobactam or cefepime
Joseph Magagnoli1, Tammy H Cummings1, Christopher M Bland2
1Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina; Center for Outcomes Research and Evaluation (CORE), College of Pharmacy, University of South Carolina, Columbia, SC, USA.
Background:
Retrospective studies have consistently reported higher rates of acute kidney injury (AKI) when vancomycin is combined with piperacillin-tazobactam compared with other β-lactams, raising concerns about nephrotoxicity. However, recent prospective studies and randomized trials have not demonstrated increased risk of clinically meaningful kidney injury, suggesting that creatinine-based endpoints may overestimate harm. We applied a multistate modelling approach to evaluate whether vancomycin-piperacillin/tazobactam is associated with progression to severe renal outcomes beyond creatinine-defined AKI.
Methods:
We conducted a retrospective cohort study using the MIMIC-IV database, including adult hospitalizations receiving vancomycin with either piperacillin-tazobactam or cefepime. A multistate model was used to evaluate transitions from antibiotic initiation to creatinine-defined AKI, dialysis, and in-hospital death. Cox proportional hazards models were fitted for each transition, with inverse probability of treatment weighting to adjust for confounding.
Results:
Among 10 490 hospitalizations, creatinine-defined AKI occurred more frequently with vancomycin-piperacillin/tazobactam than with vancomycin-cefepime (23.1% vs. 15.2%). In multistate models, piperacillin-tazobactam was associated with a higher hazard of AKI (inverse probability of treatment weighting-adjusted hazard ratio 1.63, 95% confidence interval 1.48-1.80) but not with progression to dialysis (hazard ratio 0.77, 95% confidence interval 0.50-1.19). Risks of death were similar between groups, while death following AKI was less frequent among piperacillin recipients.
Conclusions:
Although vancomycin-piperacillin/tazobactam was associated with increased creatinine-defined AKI, this did not translate into higher risks of dialysis or death. These findings support the hypothesis that observed creatinine elevations are consistent with pseudo-nephrotoxicity rather than clinically meaningful kidney injury and highlight the value of multistate modelling for interpreting drug safety signals.
Insights
Vancomycin-piperacillin/tazobactam combination is linked to higher creatinine-defined acute kidney injury (AKI), but not to increased dialysis or death risk. This suggests potential pseudo-nephrotoxicity rather than true kidney damage.
Area of Science:
- Pharmacology
- Nephrology
- Clinical Pharmacy
Background:
- Retrospective studies suggest vancomycin-piperacillin/tazobactam increases acute kidney injury (AKI) risk.
- Recent prospective data indicate creatinine-based AKI may overestimate harm from this combination.
- This study investigates severe renal outcomes beyond creatinine-defined AKI.
Purpose of the Study:
- To evaluate the association between vancomycin-piperacillin/tazobactam and severe renal outcomes.
- To compare vancomycin-piperacillin/tazobactam with vancomycin-cefepime regarding AKI progression, dialysis, and death.
- To assess if creatinine elevations signify true kidney injury or pseudo-nephrotoxicity.
Main Methods:
- Retrospective cohort study using the MIMIC-IV database.
- Inclusion of adult hospitalizations receiving vancomycin with piperacillin-tazobactam or cefepime.
- Multistate modeling with inverse probability of treatment weighting (IPTW) to analyze transitions to AKI, dialysis, and death.
Main Results:
- Creatinine-defined AKI occurred more frequently with vancomycin-piperacillin/tazobactam (23.1%) versus vancomycin-cefepime (15.2%).
- Piperacillin-tazobactam showed higher hazard for AKI (IPTW-adjusted HR 1.63) but not for progression to dialysis (HR 0.77).
- In-hospital death risks were similar; death post-AKI was less frequent with piperacillin.
Conclusions:
- Vancomycin-piperacillin/tazobactam is associated with increased creatinine-defined AKI.
- This association did not translate to higher risks of dialysis or death.
- Findings support pseudo-nephrotoxicity and highlight multistate modeling's value in drug safety assessment.
Related Concept Videos
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury I: Introduction
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications